…the biotech market has become exponentially more illogical, possibly driven by the sheer number of companies that has diluted the focus of serious investors.
Compared to when? If your “control arm” is pre-2014 (e.g.), I’m inclined to agree with your contention.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.